Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech stocks hitting 52-week highs on Dec. 13)
-
Kezar Life Sciences Inc (NASDAQ: KZR)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Dec. 13)
-
Aileron Therapeutics Inc (NASDAQ: ALRN)
-
Altimmune Inc (NASDAQ: ALT)(announced
disappointing data for Anthrax vaccine NasoShield)
-
Ardelyx Inc (NASDAQ: ARDX)
-
Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)(announced appointment of Atabak Mokari as its CFO)
-
Biocept Inc (NASDAQ: BIOC)
-
BioXcel Therapeutics Inc (NASDAQ: BTAI)
-
Cellectis SA (NASDAQ: CLLS)
-
CTI BioPharma Corp (NASDAQ: CTIC)(announced restructuring program that includes the elimination of 50
percent of workforce)
-
Cytori Therapeutics Inc (NASDAQ: CYTX)
-
DURECT Corporation (NASDAQ: DRRX)
-
Eagle Pharmaceuticals Inc (NASDAQ: EGRX)
-
Epizyme Inc (NASDAQ: EPZM)
-
Five Prime Therapeutics Inc (NASDAQ: FPRX)
-
Forward Pharma A/S (NASDAQ: FWP)
-
Genetic Technologies Limited (NASDAQ: GENE)
-
GlycoMimetics Inc (NASDAQ: GLYC)
-
Insys Therapeutics Inc (NASDAQ: INSY)
-
Leap Therapeutics Inc (NASDAQ: LPTX)
-
Mustang Bio Inc (NASDAQ: MBIO)
-
Neovasc Inc (NASDAQ: NVCN)
-
Oncomed Pharmaceuticals Inc (NASDAQ: OMED)
-
Onconova Therapeutics Inc (NASDAQ: ONTX)
-
Ophthotech Corp (NASDAQ: OPHT)
-
Orgenesis Inc (NASDAQ: ORGS)
-
Ovid Therapeutics Inc (NASDAQ: OVID)
-
Paratek Pharmaceuticals Inc (NASDAQ: PRTK)
-
Prana Biotechnology Limited (NASDAQ: PRAN)
-
SCYNEXIS Inc (NASDAQ: SCYX)
-
Second Sight Medical Products Inc (NASDAQ: EYES)
-
Sienna Biopharmaceuticals Inc (NASDAQ: SNNA)
-
TherapeuticsMD Inc (NASDAQ: TXMD)
-
Titan Medical Inc. (NASDAQ: TMDI)
-
TrovaGene Inc (NASDAQ: TROV)
-
Unum Therapeutics Inc (NASDAQ: UMRX)
-
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)
See Also: The
Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
Stocks In Focus
Axovant In-licenses Two Gene Therapies For Pediatric Lysosomal Disorder, To Offer Shares
Axovant Sciences Ltd (NASDAQ: AXON)
announced acquisition of exclusive rights for developing and commercializing two novel gene therapy programs to address GM1
gangliosidosis and GM2 gangliosidosis, both of which are pediatric lysosomal storage disorders, from the University of
Massachusetts Medical School.
The two gene therapy candidates, dubbed AXO-AAV-GM1 and AXO-AAV-GM2, would introduce copies of the respective genes encoding the
critical enzymes impacted in these diseases.
Separately, the company said it has commenced an underwritten public offering of its common shares, with all shares being sold
by the company.
The stock slid 6.19 percent to $1.06 in after-hours trading.
ZioPharma Promotes Mauney to President
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)
said it has promoted Chief Business Officer David Mauney to the role of President, effective immediately. Mauney's new role
involves leading the company's corporate and business development strategies and overseeing all operations.
The stock rose 3.09 percent to $3 in after-hours trading.
Agile To Go Ahead With Comparative Study Of Investigational Contraceptive Patch Following Meeting With FDA
Following its meeting with the FDA's Division of Bone, Reproductive, and Urologic Products on Dec. 11, Agile
Therapeutics Inc (NASDAQ: AGRX) said it expects to
conduct a crossover wear study in healthy woman with a body mass index less than 35 kg/square meter, who will be randomized either
to Twirla, its investigational low-dose once-weekly contraceptive patch, or Xulane.
Twirla was handed down a complete response letter, or CRL, in December 2017, with FDA raising concerns over deficiencies related
to, among other things, the in vivo adhesion properties and their potential relationship to the Phase 3 clinical trial results.
Agile said it will provide
additional details on the study following the receipt of the final meeting minutes from the FDA in January. The company plans to
complete the study in Q1'19 and resubmit the NDA in H1 2019, which leaves the possibility of a potential approval by the end of
2019.
Hologic Launches Non-Surgical Facelift Device In North America
Hologic, Inc. (NASDAQ: HOLX) said its
Cynosure division has launched FDA-cleared TempSure Surgical RF Technology – a platform for providing clinicians ability to perform
both surgical and non-surgical aesthetic procedures on a single device – in North America.
The company also said it has relaunched Tempsure Vitalia hand pieces and probes, while also continuing to market MonaLisa Touch
CO2 laser.
On The Radar
Clinical Trial Results
Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is expected to report preliminary results from the lower-dose cohorts of the
Phase 1/2 study of BPX-601 in patients with advanced pancreatic cancer at the ESMO Immuno-oncology conference.
Beigene Ltd (NASDAQ: BGNE) will release
Phase 1/2 data for bladder cancer treatment candidate Tislelizumab, at the ESMO Immuno-oncology conference.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.